6723-04-2

Basic information

• Product Name: (4-bromo-2-hydroxyphenyl)(phenyl)methanone
• CAS NO: 6723-04-2
• Molecular Formula: C₁₃H₉BrO₂
• Molecular Weight: 277.1134
• Mol File: 6723-04-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 357.5°C at 760 mmHg
• Flash Point: 170°C
• Density: 1.521g/cm³
• Vapor Pressure: 1.32E-05mmHg at 25°C
• Refractive Index: 1.639
• CAS DataBase Reference: (4-bromo-2-hydroxyphenyl)(phenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (4-bromo-2-hydroxyphenyl)(phenyl)methanone(6723-04-2)
• EPA Substance Registry System: (4-bromo-2-hydroxyphenyl)(phenyl)methanone(6723-04-2)

Safety Data

• Hazardous Substances Data: 6723-04-2(Hazardous Substances Data)

Usage

General Description

The chemical compound (4-bromo-2-hydroxyphenyl)(phenyl)methanone is a combination of a bromine-substituted hydroxyphenyl group and a phenylmethanone group. It is an organic compound that is often used in medicinal and pharmaceutical research. It has potential applications in the development of new drugs, particularly in the field of neuroscience and neurodegenerative diseases. Additionally, it may also have uses in the synthesis of other organic compounds and materials. The compound's specific properties and potential uses are the subject of ongoing research and investigation in the scientific community.

Upstream product

• 1666-28-0 4-bromosalicylic acid 
• 100-58-3 phenylmagnesium bromide 
• 288067-35-6 4-bromo-2-hydroxy-benzonitrile 
• 6723-03-1 6-bromo-2,3-diphenyl-benzofuran 

Downstream Products

• 335195-33-0 (4-bromo-2-hydroxy-phenyl)-phenyl-methanone oxime 
• 335195-39-6 C₁₅H₁₂BrNO₃ 

Relevant articles and documents

Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance

Microtubule targeting agents (MTAs) are among the most successful chemotherapeutic drugs, but their efficacy is often limited by the development of multidrug resistance (MDR). Therefore, the development of novel MTAs with the ability to overcome MDR is urgently needed. In this contribution, through modification of the unsymmetric biaryl compounds, we discovered a novel compound dxy-1-175 with potent anti-proliferative activity against cancer cells. Mechanistic study revealed that dxy-1-175 inhibited tubulin polymerization by interacting with the colchicine-binding site of tubulin, which caused cell cycle arrest at G2/M phase. Based on the predicted binding model of dxy-1-175 with tubulin, a series of new 4-benzoylbiphenyl analogues were designed and synthesized. Among them, the hydrochloride compound 12e with improved solubility and good stability in human liver microsome, exhibited the most potent anti-proliferative activity with IC50 value in the low nanomolar range, and markedly inhibited the growth of breast cancer 4T1 xenograft in vivo. Notably, 12e effectively overcame P-gp-mediated MDR and our preliminary data suggested that 12e may not be a substrate of P-glycoprotein (P-gp). Taken together, our study reveals a novel MTA 12e targeting the colchicine-binding site with potent anticancer activity and the ability to circumvent MDR.

Synthesis of 6-halo-1,2-benzisoxazoles, chromeno-6,7-isoxazoles and chromeno-6,7-oxazoles

-